Skip to main content
Ovoca Bio Plc logo

Ovoca Bio Plc — Investor Relations & Filings

Ticker · OVXA ISIN · IE00B4XVDC01 LEI · 213800ST2AK5XQ1O5207 IR Manufacturing
Open in API
Filings indexed 99 across all filing types
Latest filing 2024-10-09 Transaction in Own Shar…
Country IE Ireland
Listing IR OVXA

About Ovoca Bio Plc

https://ovocabio.com/

Ovoca Bio is a clinical-stage biopharmaceutical company focused on developing novel treatments for women's health. Its lead product candidate is Orenetide, a treatment for premenopausal women with hypoactive sexual desire disorder (HSDD), a condition characterized by a distressing lack of sexual desire and representing a significant area of high unmet medical need. The company is advancing Orenetide through clinical development for major global markets and has filed for marketing approval in the US and Europe. Ovoca Bio's strategy includes leveraging its patent portfolio and considering licensing or collaboration opportunities to accelerate the availability of its product candidates to patients.

Recent filings

Filing Released Lang Actions
Sale of Treasury Shares
Transaction in Own Shares Classification · 98% confidence The document is a formal announcement disseminated via RNS (Regulatory News Service), indicated by the RNS Number and the closing boilerplate text referencing the London Stock Exchange and the Financial Conduct Authority. The core content explicitly states that the Company has sold 6,895,000 ordinary shares out of treasury and provides the resulting total shares in issue. This action—the company buying back or selling its own shares—directly corresponds to the definition of 'Transaction in Own Shares'. Therefore, the appropriate filing type is POS.
2024-10-09 English
Half-year Report
Report Publication Announcement Classification · 99% confidence The document explicitly announces the 'Interim Results for the six months ended 30 June 2024' and states, 'Today we have published Ovoca's financial statements covering the six-month period to the end of June 2024'. This content describes a comprehensive financial report for a period shorter than a year, which corresponds to an Interim/Quarterly Report (IR). However, the document itself is very short (3427 chars) and primarily serves to announce the publication and provide a link to the full report ('Please click on the following link to view the full Half Year Report'). According to Rule #2 (The 'MENU VS MEAL' Rule), when a short document announces the publication of a full report, it should be classified as a Report Publication Announcement (RPA). The presence of the RNS Number and the closing statement about RNS distribution further supports this being an announcement wrapper.
2024-09-25 English
Consultancy Agreement
Regulatory Filings Classification · 98% confidence The document is a formal announcement disseminated via RNS (Regulatory News Service), indicated by the RNS Number and the closing statement referencing the London Stock Exchange and FCA. The content details the entry into a 'Consultancy Agreement' with a former Chief Executive, Mr. Kirill Golovanov, concerning advisory services and compensation. This announcement concerns a change in relationship/contract with senior personnel, which falls under Board/Management Information (MANG). Although it involves a former director, it is a specific contractual arrangement announcement rather than a general change in board composition (MANG) or executive pay disclosure (DEF 14A). However, given the context of executive transition and advisory roles, MANG is the most appropriate fit among the specific options, as it relates directly to management structure and personnel arrangements. It is not a general regulatory filing (RNS) because it fits the MANG definition more closely.
2024-09-02 English
Director/PDMR Shareholding
Director's Dealing Classification · 100% confidence The document is titled "Notification of Transactions by Persons Discharging Managerial Responsibilities and Persons Closely Associated with them" and explicitly references compliance with Article 19 of Regulation (EU) No 596/2014 (Market Abuse Regulation). It details share purchases and disposals by a Non-Executive Director (Timothy McCutcheon) and the CEO (Kirill Golovanov). This type of insider transaction reporting is specifically covered by the 'Director's Dealing' category. Although it is distributed via RNS, the specific content points directly to DIRS, which takes precedence over the general RNS fallback.
2024-07-15 English
Directorate Change
Board/Management Information Classification · 100% confidence The document explicitly announces a change in management: Kirill Golovanov is resigning as Chief Executive and Timothy McCutcheon is taking over the role. This directly corresponds to the definition of Board/Management Information (MANG). The presence of 'RNS Number' and the closing statement about RNS being the news service of the London Stock Exchange confirms it is a regulatory announcement, but the specific content dictates the classification over the general RNS fallback.
2024-07-15 English
Annual Financial Report
Report Publication Announcement Classification · 100% confidence The document explicitly states, 'Publication of 2023 Annual Report' and 'Ovoca Bio plc announces the publication of its Annual Report and Financial Statements for the year ended 31 December 2023.' It also includes a 'Letter from the CEO' discussing the 2023 full year results and mentions the Annual Report again at the end. Although it is an announcement of the report's publication (which might suggest RPA), the content provided is substantial, including detailed highlights and a CEO letter, strongly indicating this is the primary document itself, which is the Annual Report (10-K equivalent for non-US filers, but based on the definition provided, 10-K is for the 'Official yearly report covering company activity and full financial performance'). Given the context of 'Annual Report and Financial Statements' being published, 10-K is the closest fit for a comprehensive annual report, even if the filing mechanism is RNS. However, since the document is primarily an announcement *about* the publication and provides a link to the PDF, and the length is relatively short (7215 chars), it strongly aligns with the 'Menu vs Meal' rule suggesting RPA or RNS. Since it specifically announces the publication of the Annual Report, RPA (Report Publication Announcement) is the most precise fit based on the provided definitions, as it is an announcement stating the report is available, rather than the full, detailed 10-K filing itself.
2024-06-28 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.